Kenneth L McClain
Overview
Explore the profile of Kenneth L McClain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
108
Citations
4262
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Makras P, Erickson D, Davidge-Pitts C, Diamond E, Allen C, McClain K, et al.
J Clin Endocrinol Metab
. 2024 Dec;
PMID: 39699236
Endocrinopathies are frequently the initial presentation of histiocytic neoplasms, which are rare hematologic disorders affecting multiple organ systems. Langerhans cell histiocytosis and Erdheim-Chester disease are 2 such disorders known to...
2.
Bielamowicz K, Dimitrion P, Abla O, Bomken S, Campbell P, Collin M, et al.
Cancer
. 2024 Apr;
130(14):2416-2439.
PMID: 38687639
Langerhans cell histiocytosis (LCH) is a myeloid neoplastic disorder characterized by lesions with CD1a-positive/Langerin (CD207)-positive histiocytes and inflammatory infiltrate that can cause local tissue damage and systemic inflammation. Clinical presentations...
3.
Karri V, Lin H, Velazquez J, Batajoo A, Parekh D, Stanton W, et al.
Br J Haematol
. 2024 Mar;
204(5):1882-1887.
PMID: 38501390
Optimal therapeutic approaches for advanced Langerhans cell histiocytosis (LCH) are not known. We assessed the safety and efficacy of combined chemotherapy with MAPK pathway inhibition in 10 patients with refractory...
4.
Parekh D, Lin H, Batajoo A, Peckham-Gregory E, Karri V, Stanton W, et al.
Br J Haematol
. 2024 Mar;
204(5):1888-1893.
PMID: 38501389
Over 50% of patients with systemic LCH are not cured with front-line therapies, and data to guide salvage options are limited. We describe 58 patients with LCH who were treated...
5.
Stuebe C, Jenson A, Lines T, Holloman A, Cykowski M, Fung S, et al.
J Neurosurg Case Lessons
. 2024 Feb;
7(9).
PMID: 38408349
No abstract available.
6.
Wilk C, Cathomas F, Torok O, Le Berichel J, Park M, Bigenwald C, et al.
Immunity
. 2023 Dec;
56(12):2790-2802.e6.
PMID: 38091952
Neurodegenerative diseases (ND) are characterized by progressive loss of neuronal function. Mechanisms of ND pathogenesis are incompletely understood, hampering the development of effective therapies. Langerhans cell histiocytosis (LCH) is an...
7.
Wilk C, Cathomas F, Torok O, Le Berichel J, Park M, Heaton G, et al.
bioRxiv
. 2023 Oct;
PMID: 37873371
Neurodegenerative diseases (ND) are characterized by progressive loss of neuronal function. Mechanisms of ND pathogenesis are incompletely understood, hampering the development of effective therapies. Langerhans cell histiocytosis (LCH) is an...
8.
Stuebe C, Jenson A, Lines T, Holloman A, Cykowski M, Fung S, et al.
J Neurosurg Case Lessons
. 2023 Oct;
6(16).
PMID: 37870750
Background: Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis characterized histologically by foamy histiocytes and Touton giant cells in a background of fibrosis. Bone pain with long bone osteosclerosis...
9.
Geerlinks A, Scull B, Krupski C, Fleischmann R, Pulsipher M, Eapen M, et al.
Blood Adv
. 2023 Apr;
7(14):3725-3734.
PMID: 37042921
Overall survival after reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT) using alemtuzumab, fludarabine, and melphalan is associated with high rates of mixed chimerism (MC) and secondary graft failure (GF)....
10.
Eckstein O, Bernhardt M, Hood C, Karri V, Kralik S, McClain K
Pediatr Hematol Oncol
. 2023 Jan;
40(5):497-505.
PMID: 36625721
Patients with Langerhans cell histiocytosis (LCH) have been effectively treated with intravenous cytarabine. Intravenous or subcutaneous cytarabine infusions have been effective for leukemia patients, and pharmacokinetic studies have shown very...